If you are preparing an application, note that the funder has updated the scope to specifically encourage projects targeting unique pathophysiological contributors to cardiovascular disease in T1D, such as chronic inflammation, dyslipidemia, and endothelial dysfunction. Deadlines and funding limits remain unchanged, though the dedicated contact person for clinical site participation has been removed.
Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full proposal)
Funding Amounts: Up to $3,000,000 total per project over 3 years; smaller budgets considered; indirect costs allowed for non-profits (up to 10%).
Summary: Supports clinical trials of therapies to improve cardiovascular outcomes in people with type 1 diabetes, addressing a critical unmet need.
Key Information: LOI approval is required before full proposal submission; both academic and industry applicants are eligible.